StocksMediumUpdated•Originally published 9 November 2026•Updated 9 November 2026•
1 min read
ImmunityBio Revenue Jumps 53% in Q3 Alongside Positive Cancer Trial Results
Key Facts
1ImmunityBio announced that the QUILT-2.005 trial for bladder cancer treatment successfully met its primary endpoint.
ImmunityBio reported net product revenue of $48.7 million for the third quarter of 2026, representing a 53% increase year-over-year. The company stated that its U.S. revenue for the first nine months of 2026 rose 92% to $143.6 million, driven by expanded FDA approval for ANKTIVA.
This financial growth coincided with ImmunityBio announcing that its QUILT-2.005 trial met its primary endpoint, with final analysis showing the combination of ANKTIVA and BCG outperformed BCG alone for bladder cancer patients. Business Wire reported that the study provided essential clinical validation for the therapy, while IBRX closed at $8.64 on November 6, 2026.